Study to Identify Factors associated with Resilience to Clinical Dementia at Old Age - 90+ Study

Vrije Universiteit Medisch Centrum0 个研究点目标入组 114 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Age >= 90 years (for the subjects with cognitive impairment an exception will be
•made; also subjects between 85 and 90 years will be included)
•Candidate is able to walk 400 meter independently (with or without walking aid)
•No significant visual or hearing impairment (as judged by clinician),
•Cognitively intact group:
•- MMSE >= 27 points, , this inclusion criteria is not applicable to the subjects
•>= 100 years old (as a consequence of their age, they often score < 27 points
•without having dementia)
•- Clinical Dementia Rating (CDR) = 0.0 points, Cognitive impairment group:
•- MMSE: 20-28 points inclusively
•- CDR >= 0.5 point(s)
•- Determination that this dysfunction is due to cognitive functional loss and
•not physical impairment, as judged by a neurologist, internist-geriatrician or
•General Practitioner (GP)., There is an overlap in MMSE score but this has no
•effect on the contrast between the two groups. The two groups are based on
•dementia diagnosis and the MMSE score has no influence on this diagnosis.
•Someone with a MMSE of 27 can be both dement or cognitively healthy., For the
•additional follow-up visits only cognitvely intact subjects will be seen for
•questionnaires, neuropsychological examination and few physical measurements
•(smelltest, hearingtest and handgrip strength). The second follow up visit will
•be a repetition of the first, including the same subjects.

•Clinical diagnosis of severe AD
•Severe head trauma, with loss of consciousness
•Brain tumour (past, present)
•Schizophrenia, bipolar disorder, or recurrent psychotic disorders
•Stroke resulting in physical impairment
•Non-AD neurodegenerative disorders (e.g. Huntington disease, cortical basal
•degeneration, multiple system atrophy, CreutzfeldtJacob disease, primary
•progressive aphasia, Parkinson*s disease, diffuse Lewy body disease,
•frontotemporal dementia, primary vascular dementia)
•Epilepsy, currently using antiepileptic drugs (AEDs)
•Brain infections (e.g. herpes simplex encephalitis)
•Cancer with terminal life expectancy (life expectancy <12 months)
•Cancer chemotherapy or radiotherapy within the last 3 months
•Known B12 vitamin deficiency without treatment
•Uncontrolled diabetes mellitus (last measure HbA1c >80 mmol/mol)
•Known thyroid disease without treatment
•History of recreational drug use
•Alcohol consumption: >35 units per week (1 unit = 10ml of pure alcohol)
•Physical morbidity or illness which will not permit attendance at visit sessions
•Contraindication for MRI (e.g. metal implants, pacemaker etc.)
•Medications that may impair cognition, at the discretion of the investigator,
•- Benzodiazepine with known effects on cognitive functioning
•- Lithium carbonate
•- Antipsychotics including atypical agents
•- Antidepressants with known effects on cognitive functioning
•- Parkinson*s disease medicines

发起方